Related Experiment Videos
[Medical treatment of children with infantile haemangiomas]
Hanne Kalleklev Velure1, Ulla Birgitte Hartling, Anette Schuster
1anette.bygum@rsyd.dk.
Insights
Infantile haemangiomas are common benign tumors in infants. Propranolol is an effective first-line treatment for problematic infantile haemangiomas, with a new algorithm guiding decisions and monitoring.
Area of Science:
- Pediatric Dermatology
- Vascular Biology
- Oncology
Background:
- Infantile haemangioma (IH) is a common benign vascular tumor affecting 4-5% of infants.
- IH exhibits a distinct life cycle with proliferative and involution phases.
- Intervention is typically reserved for IH posing risks of functional impairment, cosmetic concerns, or complications like pain and ulceration.
Purpose of the Study:
- To present a therapeutic decision-making and monitoring algorithm for infantile haemangiomas.
- To highlight propranolol as a key first-line treatment option.
Main Methods:
- Literature review on infantile haemangioma management.
- Development of a clinical algorithm based on established treatment guidelines.
- Analysis of propranolol efficacy and safety data.
Main Results:
- Propranolol demonstrates significant efficacy as a first-line therapy for IH.
- The proposed algorithm facilitates structured therapeutic decision-making.
- Monitoring protocols are outlined for effective patient management.
Conclusions:
- Infantile haemangiomas often require no intervention due to spontaneous involution.
- Propranolol is a well-established and effective treatment for IH requiring intervention.
- The presented algorithm provides a framework for optimizing IH management and monitoring.
Abstract:
Infantile haemangioma is a benign vascular tumour seen in 4-5% of infants. It has a characteristic life cycle comprised by a proliferative phase and a spontaneous involution phase. Most infantile haemangiomas do not require intervention. Treatment is relevant when there is a risk of functional impairment or cosmetic disfigurement, or if the haemangiomas are painful and ulcerating. The beta blocker propranolol has been shown to be an excellent first-line treatment, and we present an algorithm for therapeutic decision and monitoring.